Verapamil
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Verapamil: From Unspecified Original Indication to Obsolete Bundle Branch Block
One-Sentence Summary
No original indication data is on file for this drug in the current regulatory dataset (0 licenses recorded). The TxGNN model’s top-ranked prediction is Obsolete Bundle Branch Block, with a 99.62% prediction score, but no clinical trials and no literature currently support this direction — and the mechanistic rationale provided actually argues against it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no license records on file |
| Predicted New Indication | Obsolete Bundle Branch Block |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the structured record (flagged as a High-severity data gap, DG002). The evidence pack’s own repurposing rationale, however, identifies verapamil as an L-type calcium channel blocker with negative dromotropic (conduction-slowing) activity.
This is precisely why the top-ranked prediction is not mechanistically reasonable: in patients with existing bundle branch block or AV conduction disease, verapamil’s conduction-slowing effect is a recognized risk factor requiring caution or contraindication, not a therapeutic target. The evidence pack explicitly notes the TxGNN score likely reflects node co-occurrence in the knowledge graph rather than a genuine treatment relationship, and no clinical trial or literature evidence was found to support this indication.
Given this, the top prediction should be treated as a negative/implausible signal rather than a repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No license records are available for this drug (0 NDAs on file; market status: Not Marketed). Regulatory/label data has not yet been collected — see Safety Considerations below.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug-interaction data have not yet been collected for this drug (flagged as a Blocking data gap — DG001: TFDA label warnings/contraindications — which must be resolved before any safety pre-screening, S1, can proceed).
Other TxGNN Candidates for This Drug
The evidence pack contains 7 ranked candidates for this drug, all at Evidence Level L5. Most show either no supporting evidence or a mechanistic direction that conflicts with known CCB pharmacology; one stands out as a plausible (if untested) hypothesis:
| Rank | Predicted Indication | Score | Recommendation | Note |
|---|---|---|---|---|
| 1 | Obsolete Bundle Branch Block | 99.62% | Hold | Mechanistically contradictory (see above) |
| 2 | Malignant Hypertensive Renal Disease | 99.27% | Hold | No trial/literature evidence; wrong care setting (IV titration typically needed) |
| 3 | Malignant Renovascular Hypertension | 99.27% | Hold | Cited literature not specific to verapamil treatment of this condition |
| 4 | Pulmonary HTN, unclear/multifactorial mechanism (Group 5) | 99.26% | Hold | CCBs not indicated per guidelines for this PH group |
| 5 | Pulmonary HTN due to lung disease/hypoxia (Group 3) | 99.26% | Hold | CCBs may worsen V/Q mismatch and systemic hypotension; literature is unrelated (hypoxia biology, not verapamil) |
| 6 | Braddock Syndrome | 99.15% | Hold | No known pathological link; pure KG co-occurrence signal |
| 7 | Periodic Paralysis w/ transient compartment-like syndrome | 99.08% | Research Question | Some biological plausibility via skeletal muscle calcium channel (CACNA1S) involvement; no clinical evidence yet — hypothesis-generation only |
Conclusion and Next Steps
Decision: Hold
Rationale: All candidates are L5 (model prediction only), with no clinical trials and essentially no directly relevant literature. The top-ranked candidate is mechanistically contradicted by verapamil’s known negative dromotropic effect, and a Blocking-severity data gap (missing TFDA label/warnings) prevents even an initial safety screen.
To proceed, the following is needed:
- TFDA label data (warnings, contraindications) — Blocking gap (DG001), required before any S1 safety screening
- Verapamil MOA confirmation via DrugBank — High-severity gap (DG002)
- If pursuing further, redirect research focus toward Rank 7 (periodic paralysis) as a hypothesis-generation candidate rather than the top-scored but mechanistically contradictory Rank 1 candidate
- Independent literature search specific to verapamil (current literature hits for Ranks 3 and 5 are not drug-specific and should not be counted as supporting evidence)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.